Barclays
ODT

Barclays’s Odonate Therapeutics, Inc. Common Stock ODT Stock Holding History

Barclays’s Portfolio ODT Stock Details ODT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-9,788
Closed -$29K – 4930
2021
Q3 		$29K Sell
9,788
-1,805
-16% -$6K ﹤0.01% 4281
2021
Q2 		$40K Sell
11,593
-8,137
-41% -$27.9K ﹤0.01% 4240
2021
Q1 		$68K Buy
19,730
+11,477
+139% +$217K ﹤0.01% 4132
2020
Q4 		$159K Sell
8,253
-1,630
-16% -$25.2K ﹤0.01% 3899
2020
Q3 		$132K Buy
9,883
+70
+0.7% +$1.98K ﹤0.01% 4092
2020
Q2 		$415K Buy
9,813
+4,000
+69% +$129K ﹤0.01% 3490
2020
Q1 		$160K Sell
5,813
-7,973
-58% -$232K ﹤0.01% 4465
2019
Q4 		$447K Buy
13,786
+4,677
+51% +$145K ﹤0.01% 4392
2019
Q3 		$236K Buy
9,109
+1,632
+22% +$54.6K ﹤0.01% 4848
2019
Q2 		$275K Buy
7,477
+5,559
+290% +$133K ﹤0.01% 4827
2019
Q1 		$42K Buy
1,918
+1,316
+219% +$23K ﹤0.01% 6008
2018
Q4 		$8K Sell
602
-1,941
-76% -$30.2K ﹤0.01% 6289
2018
Q3 		$49K Buy
2,543
+2,046
+412% +$41.7K ﹤0.01% 6095
2018
Q2 		$11K Sell
497
-902
-64% -$21K ﹤0.01% 6519
2018
Q1 		$30K Buy
+1,399
New +$33K ﹤0.01% 6252

Other funds holding ODT

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MA
MYDA Advisors Woodmere, New York $608M AUM 77.08% 1-Year Est. Return

Barclays's ODT Position: Q4 2021 in Review

Barclays sold out of Odonate Therapeutics, Inc. Common Stock (ODT) in Q4 2021, closing a stake of 9,788 shares — an estimated $29K sold.

Barclays first reported a position in ODT in Q1 2018 and held it in 15 quarters. The position peaked at $447K in Q4 2019. 50 funds tracked by Wall St. Rank hold ODT as of Q4 2021.

  • Barclays reported no remaining Odonate Therapeutics, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • Barclays sold 9,788 Odonate Therapeutics, Inc. Common Stock shares in Q4 2021, an estimated $29K.
  • Barclays first reported a position in Odonate Therapeutics, Inc. Common Stock in Q1 2018 and held it in 15 quarters.
  • Barclays's Odonate Therapeutics, Inc. Common Stock position peaked at $447K in Q4 2019.
  • 50 funds tracked by Wall St. Rank held Odonate Therapeutics, Inc. Common Stock as of Q4 2021.

Based on Barclays's 13F filing for Q4 2021, filed 14 Feb 2022.